linjc16/ctgov huggingface dataset:
Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians

Study Overview
=================
Brief Summary
-----------------
The normal range of retinal nerve fiber layer thickness might be different between Asians and Caucasians. However, the recently developed imaging device such as the Cirrus HD OCT includes only the Caucasian data. So, the investigators want to find its normal range of in Asians.

Detailed Description
-----------------
Characteristics of various ocular parameters are influenced by race. Because the retinal nerve fiber layer (RNFL) thickness is crucial in detecting early glaucomatous changes, its normal range is also important. Even though the normal range of RNFL thickness might be different according to race, the recently developed imaging device such as the Cirrus HD OCT includes only the Caucasian data. In the present study, we want to measure the RNFL thickness using the Cirrus HD OCT in normal Asian eyes and to determine its normal range in Asians.

Official Title
-----------------
Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects Good quality of the OCT images (signal intensity > 8) Exclusion Criteria: Any ocular history DM

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Normal subjects who received routine health check-up in a comprehensive medical testing center | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal nerve fiber layer thickness |  | when the OCT images are taking | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Refractive errors |  | when the OCT images are taking | 
| Intraocular pressure |  | when the OCT images are taking | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinal nerve fiber layer, Glaucoma, Myopia
Evaluation of Pre-deployment Device-to-artery Relative Axial Motion in Coronary Catheterizations

Study Overview
=================
Brief Summary
-----------------
The cyclic movement of the heart and the coronary arteries induces relative axial movement between the artery and a pre-deployed intra-luminal stent which may cause malpositioning. Using a new imaging algorithm to indicate the position of a stent in patients undergoing percutaneous coronary intervention (PCI), the investigators will measure the pre-deployment relative, intra-luminal stent axial movement in the different coronary arteries to facilitate the precise deployment site.

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Procedure: Routine PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing routine PCI Exclusion Criteria: Unstable patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Routine PCI patients<br> | Procedure: Routine PCI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relative axial movement of predeployed stent |  | One month |
Endometriosis and Risk of Obstetric Complications

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the rate of obstetric complications at first spontaneous pregnancy among women with endometriosis, with the rate of obstetric complications at first spontaneous pregnancy among women without endometriosis

Detailed Description
-----------------
All women followed up for a surgical or clinical/sonographic diagnosis of endometriosis in 11 italian referral Centres for the treatment of endometriosis, completed a questionnaire regarding their previous pregnancies. The same questionnaire was completed by women, attending a routine gynecologic visit, in whom surgery or clinical/sonographic evaluation excluded endometriosis.

Official Title
-----------------
Impact of Endometriosis on the Risk of Obstetric Complications in Spontaneous Pregnancy: a Multicentric Italian Study

Conditions
-----------------
Endometriosis, Pregnancy Complications

Intervention / Treatment
-----------------
* Other: Survey on first pregnancy after endometriosis diagnosis
* Other: Survey on first pregnancy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30 to 50 years old women with at least one previous spontaneous pregnancy > 12 weeks with surgical or clinical/sonographic diagnosis of endometriosis or in whom surgical or clinical/sonographic evaluation ruled out endometriosis Exclusion Criteria: Pregnancy achieved by assisted reproductive techniques Pregnancy terminated before 12 gestational weeks Twin pregnancy Preexisting hypertension Lupus like anti-coagulant Non corrected uterine malformation Recurrent abortion

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endometriosis<br>Survey on first pregnancy after endometriosis diagnosis | Other: Survey on first pregnancy after endometriosis diagnosis<br>* Obstetric complications were noted<br>|
| non endometriosis<br>Survey on first pregnancy | Other: Survey on first pregnancy<br>* Obstetric complications were noted<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-term delivery | comparison of rate of preterm delivery in the two groups | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Placenta praevia | comparison of rate of placenta praevia in the two groups | 2 years |
Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

Study Overview
=================
Brief Summary
-----------------
Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response

Official Title
-----------------
Dose Response Pharmacogenetic Study of ADHD

Conditions
-----------------
ADHD

Intervention / Treatment
-----------------
* Drug: OROS methylphenidate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6-17 DSM IV criteria for ADHD Parents willing to complete measures Exclusion Criteria: Mental retardation psychoses seizure disorder

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose) | Drug: OROS methylphenidate<br>* 18, 36, 54 mg<br>* Other names: Concerta;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADHD RS |  | weekly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CGI-S |  | weekly | 
| VItal Signs |  | weekly | 
| Sleep Questionnaire |  | weekly | 
| Side Effects rating Scale |  | weekly | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADHD, side effects, sleep, dopamine, pharmacogenetics
Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)

Study Overview
=================
Brief Summary
-----------------
Polypoidal choriodal vasculopathy (PCV) is an ophthalmologic disease, characterized by vascular abnormalities of the walls of small choroidal vessels, reproducing the specific aspect of polyps (cluster aspect). PCV is one of the boundary-forms of age related macular degeneration. These vasculopathies can be idiopathic. Following the radiotherapy treatments of active and occult-typed neovessels in Age-Related Macular Degeneration (ARMD), 10% of the patients would present typical polypoidal vasculopathic lesions. These polypoidal secondary lesions have been induced by radiotherapy treatment and may show an increased sensibility to radiation in these patients. Such an increase of radiosensibility is noticed in ataxia telangiectasia syndrome, in relation to the ATM gene mutations. The secondary or idiopathic polypoidal vasculopathic lesions are to be brought closer to telangiectasias in Ataxia Telangiectasia. Considering the iatrogenic component of radiotherapy in the secondary forms of ataxia telangiectasia, it seems legitimate to search for predisposing variants to polypoidal vasculopathies in the ATM gene. Considering the frequency of PCV worldwide, it seems important to identify the predisposing genetic factors of the ATM gene. These biomarkers to the pathology might enable us to offer prevention (reinforced protection against radiations, including light) and to develop therapeutics (recruitment of other kinases, ATM's partners, in the stability and cellular control of DNA).

Official Title
-----------------
Identification of the Predisposing Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)

Conditions
-----------------
Choroidal Neovascularization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult caucasian patient Polypoidal choriodal vasculopathy Informed written consent Exclusion Criteria: History of cephalic radiotherapy Absence of affiliation to social security or universal health coverage (CMU)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variants in the ATM gene | Compared analysis of the variants frequency (heterozygote, homozygote variants versus the wild variant) in the ATM gene. | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Polypoidal choroidal vasculopathy
BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk

Study Overview
=================
Brief Summary
-----------------
The major goals of this project are to determine whether primary intervention through delayed introduction of dietary gluten is feasible and could reduce the incidence of islet autoimmunity in high-risk first degree relatives of patients with type 1 diabetes.

Official Title
-----------------
BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Other: Glutenfree diet during the first year of life


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newborn offspring or siblings of patients with type 1 diabetes with a HLA genotype conferring a high diabetes risk Exclusion Criteria: If infants have an illness or birth defect that precludes long-term follow-up or involves use of treatment that may alter the natural history of diabetes

Ages Eligible for Study
-----------------
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Glutenfree diet<br>Glutenfree diet during the first year of life | Other: Glutenfree diet during the first year of life<br>* Glutenfree diet during the first year of life<br>|
| No Intervention: Control - normal diet<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of dietary intervention on the development of islet autoantibodies | Primary outcome is to compare the prevalence of iselt autoantibodies between children participating in the dietary intervention and the control group. | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of dietary intervention on the development of Type 1 diabetes. | Secondary outcome is to compare the prevalence of type 1 diabetes between children participating in the dietary intervention and the control group | 10 years |
Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection

Study Overview
=================
Brief Summary
-----------------
The detection of Klebsiella pneumoniae virulence gene and antibiotics resistance gene takes a long time and high cost with equipment requirements. Distinguishing the Klebsiella pneumoniae by gene were late for clinical treatment. Therefore, the investigators aim to study the clinical characteristics of critically ill patients with Klebsiella pneumoniae infection which expressed different drug sensitivity test results.

Detailed Description
-----------------
Clinical data of adult patients in integrated ICUs of 6 hospitals of Fujian Province China from January 2015 to July 2019 were collected, who had been examined for sputum, urine, blood, pleural effusion, ascites, cerebrospinal fluid and wound secretions and other body fluid samples. And the results showed that Klebsiella pneumoniae was positive, including demographic data, underlying disease status, drug sensitivity test, infection-related indicators, life support, prognostic indicators.

Official Title
-----------------
Analysis of the Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection: A Multi-center Research in the Intensive Care Units

Conditions
-----------------
Drug Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult whose body fluid were sampled during ICU stay and Klebsiella pneumoniae was detected, followed by drug sensitivity test (including reporting the test results after the patient was transferred out of ICU or died). Exclusion Criteria: Age were less than 18 years old; Patients stayed in ICU was less than 48 hours.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Klebsiella pneumoniae<br>patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognostic indicators | 30-day survival rate | 30 day | 
| ICU stays | the length that patients stay in ICU | about a mouth |
The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy

Study Overview
=================
Brief Summary
-----------------
Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.

Official Title
-----------------
Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking

Conditions
-----------------
Bullous Keratopathy

Intervention / Treatment
-----------------
* Radiation: ultraviolet-A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with bollous keratopathy Exclusion Criteria: corneal scarring or contemporary eye disease affecting VA were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
This is a 16 day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery

Conditions
-----------------
Cataract Extraction

Intervention / Treatment
-----------------
* Drug: ketorolac eye drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing cataract surgery Exclusion Criteria: Uncontrolled ocular disease in cataract surgery eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: ketorolac eye drops<br>* 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day Placebo<br>|
| Placebo Comparator: 2<br> | Drug: ketorolac eye drops<br>* 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of Post Operative Inflammation | Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular Pain | Measured on a scale of 0-4 (0 = none, 4 = intolerable) | Day 1 | 
| Mean Pupil Area | Pupil area post-irrigation and aspiration | Day 0 |
The Women's Health Study: From Adolescence to Adulthood

Study Overview
=================
Brief Summary
-----------------
In order to learn more about women's health issues that occur over the lifespan, the Women's Health Study: from Adolescence to Adulthood is building a biorepository and database. The biorepository collects, processes and stores samples (such as urine, saliva, blood, cells, tissue and peritoneal fluid) until they are needed for research. The database contains de-identified information about our study participants. The biorepository and database are being created to serve as a resource for researchers from Boston Children's Hospital, Brigham and Women's Hospital and outside institutions.

Official Title
-----------------
The Women's Health Study: From Adolescence to Adulthood Sponsored by the Boston Center for Endometriosis.

Conditions
-----------------
Infertility, Pelvic Pain, Endometriosis, Dysmenorrhea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female at least 7 years old not experiencing natural menopause Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Females with endometriosis<br>Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group. | |
| Females without surgical diagnosis of endometriosis<br>Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establishing a biorepository and database |  | next 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
women's health, endometriosis, dysmenorrhea, pelvic pain, adolescence, biorepository, observational, women, female, gynecology, fertility, infertility